Vikas Kotagal1, Christina Lineback2, Nicolaas I Bohnen3, Roger L Albin4. 1. Department of Neurology, University of Michigan, Ann Arbor, MI, United States; Neurology Service and GRECC, VAAAHS, Ann Arbor, MI, United States. Electronic address: vikaskot@med.umich.edu. 2. Department of Neurology, University of Michigan, Ann Arbor, MI, United States. 3. Department of Neurology, University of Michigan, Ann Arbor, MI, United States; Neurology Service and GRECC, VAAAHS, Ann Arbor, MI, United States; Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, United States; University of Michigan Morris K. Udall Center of Excellence for Parkinson's Disease, Ann Arbor, MI, United States. 4. Department of Neurology, University of Michigan, Ann Arbor, MI, United States; Neurology Service and GRECC, VAAAHS, Ann Arbor, MI, United States; University of Michigan Morris K. Udall Center of Excellence for Parkinson's Disease, Ann Arbor, MI, United States.
Abstract
BACKGROUND: Orthostatic hypotension is increasingly reported as a risk factor for development of late-stage disease features in Parkinson disease (PD). Less is known about its significance in individuals with early PD who are often targeted for neuroprotective trials. METHODS: Using data from the CALM-PD trial (n = 275), we explored whether early orthostatic hypotension predicts a decline in the Unified Parkinson's Disease Rating Scale (UPDRS) II (activities of daily living) or UDPRS III (motor) score after 102 weeks. We also explored risk factors for worsening orthostatic hypotension over a nearly 2-year period. RESULTS: After controlling for age, disease duration, gender, study drug, change in mini-mental status exam score, levodopa equivalent dose, and baseline UPDRS II or III score respectively, the degree of orthostatic hypotension at enrollment associated with a worsening in UPDRS motor score (t = 2.40, p = 0.017) at week 102 but not with UPDRS ADL score (t = 0.83, p = 0.409). Worsening in orthostatic hypotension during the study associated with longer disease duration (t = 2.37, p = 0.019) and lower body mass index (BMI) (t = -2.96, p = 0.003). CONCLUSIONS: Baseline orthostatic hypotension is a predictor of UPDRS motor decline in individuals with early PD and should be accounted for in clinical trial design. Low BMI may predict orthostatic hypotension in PD.
BACKGROUND:Orthostatic hypotension is increasingly reported as a risk factor for development of late-stage disease features in Parkinson disease (PD). Less is known about its significance in individuals with early PD who are often targeted for neuroprotective trials. METHODS: Using data from the CALM-PD trial (n = 275), we explored whether early orthostatic hypotension predicts a decline in the Unified Parkinson's Disease Rating Scale (UPDRS) II (activities of daily living) or UDPRS III (motor) score after 102 weeks. We also explored risk factors for worsening orthostatic hypotension over a nearly 2-year period. RESULTS: After controlling for age, disease duration, gender, study drug, change in mini-mental status exam score, levodopa equivalent dose, and baseline UPDRS II or III score respectively, the degree of orthostatic hypotension at enrollment associated with a worsening in UPDRS motor score (t = 2.40, p = 0.017) at week 102 but not with UPDRS ADL score (t = 0.83, p = 0.409). Worsening in orthostatic hypotension during the study associated with longer disease duration (t = 2.37, p = 0.019) and lower body mass index (BMI) (t = -2.96, p = 0.003). CONCLUSIONS: Baseline orthostatic hypotension is a predictor of UPDRS motor decline in individuals with early PD and should be accounted for in clinical trial design. Low BMI may predict orthostatic hypotension in PD.
Authors: Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen Journal: Neurology Date: 2014-03-28 Impact factor: 9.910
Authors: Marjolein A van der Marck; Heleen C Dicke; Ergun Y Uc; Zippora H A Kentin; George F Borm; Bastiaan R Bloem; Sebastiaan Overeem; Marten Munneke Journal: Parkinsonism Relat Disord Date: 2011-11-18 Impact factor: 4.891
Authors: Seyed-Mohammad Fereshtehnejad; Silvia Rios Romenets; Julius B M Anang; Véronique Latreille; Jean-François Gagnon; Ronald B Postuma Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302
Authors: Elisabetta Indelicato; Alessandra Fanciulli; Werner Poewe; Angelo Antonini; Francesco E Pontieri; Gregor K Wenning Journal: Parkinsonism Relat Disord Date: 2015-11-03 Impact factor: 4.891
Authors: Claudia Ledda; Elisa Montanaro; Leonardo Lopiano; Alberto Romagnolo; Gabriele Imbalzano; Aristide Merola; Ilaria Bruno; Carlo Alberto Artusi; Maurizio Zibetti; Mario Giorgio Rizzone; Marco Bozzali; Gabriele Sobrero; Fabrizio Vallelonga; Simona Maule Journal: Clin Auton Res Date: 2022-08-28 Impact factor: 5.625
Authors: Zuzanna Tkaczynska; Sara Becker; Walter Maetzler; Maarten Timmers; Luc Van Nueten; Patricia Sulzer; Giacomo Salvadore; Eva Schäffer; Kathrin Brockmann; Johannes Streffer; Daniela Berg; Inga Liepelt-Scarfone Journal: Front Aging Neurosci Date: 2020-03-06 Impact factor: 5.750